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Olivier Muller, MD, PHD,* Filip Casselman, MD, PHD,‡ Bart De Wiest, RN,§ Romaric Croes, MD,
Sofie Verstreken, MD,* Marc Goethals, MD,* Herbert de Raedt, MD,* Jaydeep Sarma, MD, PHD,*
Lija Joseph, MD,¶ Marc Vanderheyden, MD,*† Ellen O. Weinberg, PHD¶
Aalst and Dendermonde, Belgium; and Boston, Massachusetts
Objectives This study was designed to investigate: 1) relationships between serum ST2 levels and hemodynamic/neurohor-
monal variables; 2) myocardial ST2 production; and the 3) expression of ST2, membrane-anchored ST2L, and its
ligand, interleukin (IL)-33, in myocardium, endothelium, and leukocytes from patients with left ventricular (LV)
pressure overload and congestive cardiomyopathy.
Background Serum levels of ST2 are elevated in heart failure. The relationship of ST2 to hemodynamic variables, source of
ST2, and expression of ST2L and IL-33 in the cardiovascular system are unknown.
Methods Serum ST2 (pg/ml; median [25th, 75th percentile]) was measured in patients with LV hypertrophy (aortic steno-
sis) (n  45), congestive cardiomyopathy (n  53), and controls (n  23). ST2 was correlated to N-terminal pro-
brain natriuretic peptide, C-reactive protein, and hemodynamic variables. Coronary sinus and arterial blood sam-
pling determined myocardial gradient (production) of ST2. The levels of ST2, ST2L, and IL-33 were measured
(reverse transcriptase-polymerase chain reaction) in myocardial biopsies and leukocytes. The ST2 protein pro-
duction was evaluated in human endothelial cells. The IL-33 protein expression was determined (immunohisto-
chemistry) in coronary artery endothelium.
Results The ST2 protein was elevated in aortic stenosis (103 [65, 165] pg/ml, p  0.05) and congestive cardiomyopathy
(194 [69, 551] pg/ml, p  0.01) versus controls (49 [4, 89] pg/ml) and correlated with B-type natriuretic pep-
tide (r  0.5, p  0.05), C-reactive protein (r  0.6, p  0.01), and LV end-diastolic pressure (r  0.38, p 
0.03). The LV ST2 messenger ribonucleic acid was similar in aortic stenosis and congestive cardiomyopathy ver-
sus control (p  NS). No myocardial ST2 protein gradient was observed. Endothelial cells secreted ST2. The
IL-33 protein was expressed in coronary artery endothelium. Leukocyte ST2L and IL-33 levels were highly corre-
lated (r  0.97, p  0.001).
Conclusions In human hypertrophy and failure, serum ST2 correlates with the diastolic load. Though the heart, endothelium,
and leukocytes express components of ST2/ST2L/IL-33 pathway, the source of circulating serum ST2 is
extra-myocardial. (J Am Coll Cardiol 2008;52:2166–74) © 2008 by the American College of Cardiology
Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.09.027n
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bnflammatory/innate immune signaling contributes to the
athophysiology of human hypertrophy and heart failure.
ecently, serum ST2 protein has emerged as a new prog-
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ccepted September 22, 2008.ostic biomarker in patients with recent myocardial infarc-
ion and congestive heart failure (1–6). The ST2 protein,
nd its membrane-anchored counterpart, ST2L, belong to
he Toll-interleukin (IL)-1 receptor family and production
f both isoforms from a single messenger ribonucleic acid
mRNA) is transcriptionally regulated (7,8). Extracellular
ngagement of ST2L with its ligand, IL-33, leads to the
nduction of Th2 cytokines in T cells (9) and down-
egulation of Toll-like receptor 4 signaling (10–12). Soluble
T2 protein is secreted in response to inflammatory signals.
t inhibits the binding of IL-33 to ST2L (13) and has also
een shown to bind to macrophages leading to down-
egulation of proinflammatory cytokines (14–16). Separate
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December 16/23, 2008:2166–74 Nonmyocardial ST2 Production and Diastolic Loadtudies identified IL-33 as an intracellular protein localizing
o the nucleus in inflamed high endothelial venules (17,18).
Apart from prognostic information obtained from soluble
T2 serum levels, little is known about myocardial produc-
ion of ST2 or regulation and expression of ST2, ST2L, and
L-33 (9) in the cardiovascular system. Serum ST2 strongly
orrelated with serum B-type natriuretic peptide (BNP) and
ro-atrial natriuretic peptide (3), which are released from
he myocardium in response to pressure or volume overload
nd relate to indexes of hemodynamic load (19). The ST2
evels also correlated with serum levels of norepinephrine
3), a marker of systemic neurohormonal activation in the
ailing heart. However, whether hemodynamic factors are
irectly related to serum ST2 levels in human hypertrophy
nd failure is unknown.
We tested the hypothesis that serum ST2 levels correlate
o hemodynamic variables in patients with pressure overload
ypertrophy and congestive cardiomyopathy (CCM). Both
onditions represent 2 distinct pathophysiological mecha-
isms of heart failure allowing us to pin down hemodynamic
ariables related to elevated serum ST2. Furthermore, we
valuated the myocardium as the origin of serum ST2 by
nvestigating expression levels in myocardial biopsies as well
s protein production of ST2. Finally, we report new
nformation on secretion of ST2 protein in endothelial cells
nd expression of ST2L and IL-33 in the myocardium and
eripheral leukocytes from patients with pressure overload
ypertrophy and CCM.
ethods
atients. A total of 223 patients were studied. Serum ST2
evels were determined in 163 patients: 50 consecutive
atients with symptomatic aortic stenosis (AS), 87 patients
ith congestive heart failure referred for elective diagnostic
eft-right heart catheterization (CCM), and a control group
hat consisted of 26 subjects in whom diagnostic cardiac
atheterization showed normal coronary angiogram and left
entricular (LV) function. In addition, 14 patients present-
ng with diastolic heart failure defined by elevated filling
ressures and preserved LV systolic function were included
or ST2 determination. Patients presenting with acute
oronary syndrome, systemic inflammation, or active infec-
ion were excluded. For determination of myocardial BNP
nd ST2 production, coronary sinus and arterial blood were
ampled during cardiac catheterization from 24 patients
ith advanced congestive heart failure. In 38 patients
details follow) LV myocardial gene expression for ST2,
T2L, IL-33, and BNP was performed. The study was
pproved by the institutional ethics committee, and all
atients gave informed consent.
emodynamics. At catheterization, pulmonary capillary
edge pressure was measured by a Swan-Ganz catheter,
hereas LV pressure was recorded with a catheter posi-ioned in the LV cavity. The LV volumes and ejection craction were derived from the
ingle-plane angiogram using the
rea-length method. Aortic valve
rea was calculated using the
orlin formula.
Echo-Doppler was performed
mmediately before or after car-
iac catheterization according to
uidelines of the American Society
f Echocardiography (20). The
V end-diastolic and -systolic me-
idional wall stress were calculated
rom M-mode in combination
ith pressure data as previously
escribed (21). The LV mass was
alculated by the Devereux et al.
22) equation. Increased diastolic
oad is defined as LV end-diastolic
ressure (EDP)16 mm Hg (23).
erum measurements. The ST2
rotein was measured by enzyme-linked immunoadsorbent
ssay (MBL International, Inc., Woburn, Massachusetts). The
nzyme-linked immunoadsorbent assay coefficient of variation
nd stability of ST2 have been described (1,4–6). N-terminal
ro-brain natriuretic peptide (NT-proBNP) was measured
sing automated enzyme immunoassay (Roche Diagnostics,
asel, Switzerland). High-sensitivity C-reactive protein
hsCRP) was determined using an immunoturbidimetric
ethod with latex beads coated with anti-CRP–specific anti-
ody (Roche Diagnostics).
V biopsies. The LV endomyocardial biopsies were ob-
ained from 38 patients (9 control, 12 AS, and 17 CCM).
ontrol biopsies were obtained from patients with normal
V function and stable angina pectoris referred for elective
ardiac bypass surgery. In the control and AS groups, LV
iopsies were obtained during cardiac surgery and in pa-
ients with congestive CCM during routine cardiac
atheterization.
ultured cells. Human saphenous vein endothelial cells
ere cultured in endothelial media at passages 3 to 5.
uman coronary artery endothelial cells were obtained from
onza (Allendale, New Jersey). Culture supernatant was
ssayed for ST2 16 h after treatment, or, for time course,
hen indicated. Phorbol ester (200 nmol/l), H2O2 (50
mol/l), and brefeldin A (5 mol/l) were obtained from
igma (St. Louis, Missouri); IL-1-beta (5 ng/ml), and
umor necrosis factor-alpha (10 ng/ml) were obtained from
& D Systems (Minneapolis, Minnesota).
ibonucleic acid (RNA) extraction. RNA was extracted
sing the RNeasy Mini Kit (Qiagen, Venlo, the Nether-
ands) and was deoxyribonuclease digested and reverse
ranscribed using High-Capacity cDNA Archive System
Applied Biosystems, Foster City, California).
everse transcriptase-polymerase chain reaction. Real-
ime reverse transcriptase-polymerase chain reaction on
Abbreviations
and Acronyms
AS  aortic stenosis
AU  arbitrary units
BNP  B-type natriuretic
peptide
CCM  congestive
cardiomyopathy
EDP  end-diastolic
pressure
hsCRP  high sensitivity
C-reactive protein
IL  interleukin
LV  left ventricular
mRNA  messenger
ribonucleic acid
NT-proBNP  N-terminal
pro-brain natriuretic peptideomplementary deoxyribonucleic acids was performed in
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Nonmyocardial ST2 Production and Diastolic Load December 16/23, 2008:2166–74riplicate using Assay-on-Demand (ST2) or specific primers
nd TaqMan minor groove binder probes (ST2L-F: 5=-
AGGCGGCACATTTTCATC-3=, ST2L-R 5=-
GCTCGTAGGCAAACTCCTTATT-3=, ST2L-probe
-FAM-ACCCCTCAGATCACTC-MGB and IL-33-F:
=-CCAGGCCTTCTTTGTCCTTCATAAT-3=, IL-
3-R 5=-CTCCAGGATCAGTCTTGCATTCAA-3=,
L-33-probe 6-FAM-CACTCCAACTGTGTTTCAT-
GB) (ABI Prism 7000 Sequence Detection System,
pplied Biosystems). Expression of ST2, ST2L, and IL-33
as normalized to glyceraldehyde 3-phosphate dehydroge-
ase (Applied Biosystems) in the same sample.
mmunohistochemistry. Immunohistochemistry for IL-33 was
erformed on a human coronary artery using an affinity
urified rabbit polyclonal antibody against an IL-33 peptide
ntigen (Affinity Bioreagents, Golden, Colorado) and dia-
inobenzidine staining with antigen retrieval (Vector Lab-
ratories, Burlingame, California).
tatistical analyses. Data were analyzed using GraphPad
rism (La Jolla, California) and are presented as mean 
D for normally distributed variables and as median [25th,
5th percentile] when non-Gaussian distributed. For 3
roups, data were analyzed by analysis of variance for
arametric analysis or the Kruskal-Wallis test for nonpara-
etric analysis and, when significant (p  0.05), were
ollowed by Dunn or Bonferroni multiple comparison test-
ng, respectively. For 2 groups, data were analyzed using
tudent t test with p  0.05 considered significant. When
ariables displayed heterogeneity of variance, data were
ransformed and are presented on a logarithmic scale.
earson correlation was used for normally distributed vari-
bles and Spearman correlation was used for nonparametric
ariables.
esults
atient characteristics. Baseline characteristics of control,
S, and CCM patients undergoing serological analyses are
hown in Table 1. The LV mass index was higher in AS and
CM patients compared with the index in control patients.
he CCM patients had larger end-diastolic volumes, lower
jection fractions, and higher diastolic and systolic wall
tress compared with the same measurements in control
atients. The LV EDP was elevated in the AS and CCM
roups compared with the LV EDP in the control group.
eft ventricular developed pressure increased in the AS
roup and decreased in the CCM group compared with
eveloped pressure in the control group. There were no
ifferences in clinical or hemodynamic characteristics be-
ween both subpopulations. In both populations 64% and
2% of CCM patients, respectively, presented with acute
ecompensation or worsening of congestive heart failure
ymptoms.
erum ST2, hsCRP, and NT-proBNP levels. Serum
evels of ST2 (Fig. 1A, left) were significantly increased in
atients with AS (103 [65, 165] pg/ml, p  0.05) and wCM (194 [69, 551] pg/ml, p  0.01) compared with
erum levels in control patients (49 [4, 89] pg/ml). Levels of
T-proBNP (Fig. 1A, middle) were significantly increased
n AS (537 [253, 1,936] pg/ml, p  0.05) and CCM
atients (3,088 [629, 7,846] pg/ml, p 0.01) versus control
atients (43 [28, 100] pg/ml). Levels of hsCRP (Fig. 1A,
ight) were significantly increased in patients with AS (6.1
1.3, 15] mg/l, p  0.05) and CCM (12.0 [3.3, 29.2] mg/l,
 0.01) versus control patients (2.2 [1.2, 3.0] mg/l). In the
ntire population, a significant positive relationship was
oted between ST2 and NT-proBNP (Fig. 1B, left) (r 
.47, p  0.05) and between ST2 and hsCRP (Fig. 1B,
ight) (r  0.55, p  0.001).
erum ST2 and hemodynamic parameters. No significant
elationship was noted between serum ST2 levels and
ndices of LV remodeling including LV end-diastolic or
systolic volume, LV mass index, and LV relative wall
hickness. Furthermore, ST2 levels did not correlate with
V systolic developed pressure or systolic wall stress. How-
ver, in the entire study population, a weak but significant,
nverse relationship was noted between ST2 levels and LV
jection fraction (r  –0.21, p  005). On the other hand,
T2 levels showed a stronger relationship with LV EDP (r 
.37, p  0.01).
T2 and diastolic load. In the entire cohort (Fig. 2A),
erum ST2 levels were higher in patients with moderately or
everely elevated LV EDP as compared with patients with
ormal or mildly increased LV EDP. The ST2 levels were
ncreased proportionally with the extent of diastolic load as
ssessed from elevated levels of LV EDP (Fig. 2B).
To further determine whether diastolic load is associated
linical and Hemodynamic Parametersf Patients With Serologic l Analy es
Table 1 Clinical and Hemodynamic Parametersof Patients With Serological Analyses
Control
(n  23)
AS
(n  45)
CCM
(n  53)
Age, yrs 60 15 73 8 65 14
Female/male 10/13 24/21 20/33
NYHA functional class, I/II/III/IV, % 100/0/0/0 17/36/47/0 2/48/31/19
Acute heart failure NA 6 (13%) 34 (64%)
Coronary artery disease 0 7 (15%) 13 (24%)
Beta-blockers 5 (22%) 20 (45%) 40 (75%)
ACE/AT1 blockers 3 (13%) 19 (42%) 46 (87%)
Diuretics 2 (9%) 22 (49%) 50 (94%)
LV mass index, g/m2 75 28 128 59* 136 67*
EDVI, ml 80 24 79 30 127 56†‡
LV ejection fraction, % 74 10 68 21 27 11†§
LV developed pressure, mm Hg 133 31 174 44* 97 30§
LV EDP, mm Hg 12 4 18 8* 23 8†
Diastolic wall stress, kdyn/cm3 14 7 21 10 40 22†§
Systolic wall stress, kdyn/cm3 93 25 74 35 120 58§
alues are mean  SD. Data were analyzed by analysis of variance followed by post-hoc analysis.
p 0.01 versus control; †p 0.001 versus control; ‡p 0.001 versus AS; §p 0.01 versus AS;
p  0.05 versus control.
ACE angiotensin-converting enzyme; AS aortic stenosis; AT1 angiotensin II type 1; CCM
ongestive cardiomyopathy; EDP  end-diastolic pressure; EDVI  end-diastolic volume index;
V  left ventricular; NYHA  New York Heart Association.ith ST2 levels independent of LV systolic function (ejection
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December 16/23, 2008:2166–74 Nonmyocardial ST2 Production and Diastolic Loadraction), ST2 was examined in patients (n  14) presenting
ith isolated diastolic heart failure and normal LV systolic
unction (Fig. 3A, left). Serum ST2 was higher in these
atients compared with ST2 levels in control patients (383 
49 pg/ml vs. 75  12 pg/ml, p  0.001). Likewise, NT-
roBNP also increased compared with the levels in control
Figure 1 Serum Levels of Humoral Markers
(A) Serum levels of ST2, CRP, and BNP in AS, CCM, and control patients. Box plo
(left) and CRP and ST2 (right) in all patients. *p  0.05 versus control; **p  0
B-type natriuretic peptide; CCM  congestive cardiomyopathy; hsCRP  high sens
Figure 2 Relationship Between Serum ST2 Levels and Extent o
Serum ST2 levels according to LV EDP in all study subjects (A) and in control and
[25th, 75th percentile]. CCMP  congestive cardiomyopathy patients; LV EDP  leatients (901 293 pg/ml vs. 88 31 pg/ml, p 0.001) (Fig.
A, right). The corresponding LV EDP (18 10 mm Hg vs.
2 4 mm Hg, p 0.03) and ejection fraction (73 13% vs.
4 7%, p NS) are shown (Fig. 3B). These results suggest
hat diastolic load is a hemodynamic factor that modulates ST2
roduction.
w median [25th, 75th percentile]. (B) Scatterplot between NT-proBNP and ST2
ersus control; ***p  0.005 AS versus control. AS  aortic stenosis; BNP 
-reactive protein; NT-proBNP  N-terminal pro-brain natriuretic peptide.
stolic Load as Assessed From LV EDP
patients (B). Box plots show median
tricular end-diastolic pressure; other abbreviations as in Figure 1.ts sho
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Nonmyocardial ST2 Production and Diastolic Load December 16/23, 2008:2166–74yocardial production of BNP and ST2. To determine
yocardial production of BNP and ST2, the coronary sinus
inus arterial blood concentration gradient was determined
n 24 patients with chronic heart failure undergoing implan-
ation of biventricular pacemakers. Hemodynamic character-
stics of these patients with corresponding LV EDP (22  9
m Hg vs. 23  9 mm Hg, p  NS) and ejection fraction
27  9% vs. 27  9%, p  NS) were similar to the CCM
roup undergoing serological analyses. Arterial and coro-
ary sinus levels of NT-proBNP were 1,069  933 pg/ml
nd 1,798  1,178 pg/ml, respectively, with a difference of
29 410 pg/ml, p 0.0001 sinus versus arterial (Fig. 4A,
eft). Arterial and sinus levels of ST2 were 275 195 pg/ml
nd 264 171 pg/ml, respectively, with a difference of –11
9 pg/ml, p  NS (Fig. 4A, right). These results demon-
trate myocardial production of BNP but not of ST2. In LV
yocardial biopsies (characteristics presented in Table 2),
NP mRNA levels were 4.4-fold increased in AS (log
rbitrary units [AU]: 0.98  1.16) and 43-fold in CCM
log AU: 2.71  0.41) patients compared with the levels in
ontrol patients (log AU: 0.27  1.11, p  0.001) (Fig. 4B,
eft). Serum NT-proBNP levels correlated with their cor-
esponding myocardial BNP mRNA levels (samples from
he same patients, r  0.54, p  0.01). The ST2 mRNA
evels were not significantly increased in AS (log AU: 0.73
Figure 3 Serum ST2 and BNP in Patients With Isolated Diastol
(A) Serum ST2 (left) and BNP (right) levels in patients with isolated diastolic failu
scale. (B) The LV EDP (left) and LV ejection fraction (right) in patients with diasto
and 2..66) and CCM patients (log AU: 0.85  0.39) compared mith the levels in control patients (log AU: 0.55  0.20, p 
S) (Fig. 4B, right) with no correlation between serum ST2
nd myocardial ST2 mRNA.
T2 secretion by venous and arterial endothelial
ells. Phorbol-ester induced ST2 secretion in venous
ndothelial cells compared with ST2 secretion in control
atients (299  22 pg/ml vs. 92  6 pg/ml, p  0.001)
Fig. 5). Interleukin-1-beta induced ST2 secretion in
enous and arterial endothelial cells (venous: 125  6
g/ml vs. 92  6 pg/ml, p  0.001; arterial: 103  48
g/ml vs. 50  24 pg/ml, p  0.05). Tumor necrosis
actor-alpha also induced ST2 secretion (115  4 pg/ml)
ompared with secretion in control cells (96  6 pg/ml,
 0.001). The H2O2 blocked basal ST2 secretion in
ndothelial cells (16  4 pg/ml vs. 50  24 pg/ml, p 
.05), demonstrating that local oxidative stress can in-
ibit ST2 secretion. The ST2 secretion was elevated by
h compared with secretion in control patients (150 
0 pg/ml vs. 52  12 pg/ml, p  0.001), reached peak
evels at 6 h (304  14 pg/ml vs. 51  10 pg/ml, p 
.001) (Fig. 5, right), and declined afterward (not
hown). Brefeldin A, a blocker of protein secretion
hrough the endoplasmic reticulum and Golgi apparatus,
n the presence of phorbol ester completely blocked ST2
ecretion (Fig. 5, right). Data represent 3 to 4 experi-
ta were transformed due to heterogeneity of variance into the logarithmic
re versus control patients. HF  heart failure; other abbreviations as in Figures 1ic HF
re. Da
lic failuents with duplicate samples.
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December 16/23, 2008:2166–74 Nonmyocardial ST2 Production and Diastolic Loadxpression of IL-33 and ST2L in the heart and endo-
helium. The IL-33 mRNA levels were modestly lower
n LV biopsies from AS patients (0.80  0.33 AU)
ompared with levels in biopsies from CCM patients
1.33  0.48 AU, p  0.005) (Fig. 6A, left). Levels of
embrane-anchored ST2L were significantly decreased
n AS patients compared with levels in control patients
0.27  0.22 AU vs. 1.00  0.60 AU; p  0.05), but
evels were similar between CCM (0.92  0.72 AU) and
ontrol patients (p  NS) (Fig. 6A, left). The IL-33
rotein localizes to endothelial cells in the human coro-
ary artery (Fig. 6B). A weak correlation between IL-33
nd ST2L mRNA expression in myocardial biopsies was
bserved (r  0.35, p  0.045).
eripheral leukocyte expression of ST2, ST2L, and
L-33. Levels of soluble ST2 mRNA in peripheral leuko-
ytes were similar in all groups (control: 2.0  1.4 AU; AS:
.3 3.6 AU; CCM: 4.2 2.8 AU; pNS) as were levels
f ST2L (control: 20.1  15.9 AU; AS: 23.8  17 AU;
CM: 16.0 14 AU; p NS) and IL-33 (control: 0.94
.84 AU; AS: 1.13 1.1 AU; CCM: 0.63 0.77 AU; p
S). However, a strong correlation was noted between
L-33 and ST2L mRNA in leukocytes over the range of all
Figure 4 Transmyocardial Gradient of and Myocardial mRNA Le
(A) Transmyocardial production of BNP (left) and ST2 (right) in individual patients
ues. (B) The LV BNP mRNA levels (left) in control, AS, and CCM cardiac biopsies.
trary units; mRNA  messenger ribonucleic acid; other abbreviations as in Figurealues (r  0.996; p  0.001) (Fig. 7). tiscussion
he present study shows that serum ST2 protein is elevated
n patients with chronic LV pressure overload due to AS as
ell as in patients with congestive heart failure. The ST2
ositively correlated with NT-proBNP and the inflamma-
ory marker CRP. The ST2 levels were proportionally
elated to the extent of diastolic load. A dominant role of
iastolic load in relationship to ST2 levels is further sup-
orted by findings in a subgroup of patients with normal
ystolic function and isolated diastolic failure. In this group,
T2 levels were increased as were NT-proBNP levels. Thus,
T2 induction appears to be sensitive primarily to diastolic
oad. However, it is interesting that unlike BNP induction
19,23), ST2 production did not show a significant relation-
hip with systolic wall stress.
The source of serum ST2 in cardiovascular disease was
resumed to be myocardial following in vitro data showing
oad induction of ST2 mRNA in neonatal rat cardiac
yocytes (24). We provide direct evidence that the adult,
uman myocardium is not the source of increased serum
T2 in pressure overload hypertrophy and congestive car-
iomyopathy. First, it is well established that ST2 is
of BNP and ST2
24) with heart failure. Mean  SD are also shown in addition to individual val-
V ST2 mRNA levels (right) are not significantly different in all groups. AU  arbi-vels
(n 
The L
1.ranscriptionally regulated (mRNA induction) (7,8), yet
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Nonmyocardial ST2 Production and Diastolic Load December 16/23, 2008:2166–74T2 mRNA levels were not significantly increased in
yocardial biopsies. This is in contrast with BNP expres-
ion, which was increased in the same RNA pool of LV
amples reflecting increased levels of serum NT-proBNP in
he same patients. Second, direct measurements of the BNP
nd ST2 protein concentration in coronary sinus and arterial
lood samples demonstrated a transmyocardial gradient
production) of BNP, but no transmyocardial gradient of
T2. These surprising findings prompted us to examine
T2 protein production in extra-myocardial, nonmyocyte
ell types. We present the novel findings that human venous
Figure 5 ST2 Protein Secretion by Human Venous and Arterial
Phorbol ester, IL-1-beta, and TNF-alpha induced ST2 secretion in venous endotheli
thelial cells (middle). Time course shows ST2 is rapidly synthesized and secreted
din A blocked ST2 secretion (right). IL  interleukin; TNF  tumor necrosis factor
linical and Hemodynamic Parametersf Patients With Gene Expression Analysis
Table 2 Clinical and Hemodynamic Parametersof Patients With Gene Expression Analysis
Control
(n  9)
AS
(n  12)
CCM
(n  17)
Age, yrs 61 13 71 9 58 16
Female/male 1/8 6/6 4/13
NYHA functional class, I/II/III/IV, % 100/0/0/0 25/67/8/0 6/42/35/17
Acute heart failure NA 2 (12%) 9 (52%)
Coronary artery disease 6 (66%) 3 (25%) 3 (17%)
Beta-blockers 4 (44%) 1 (8%) 10 (57%)
ACE/AT1 blockers 4 (44%) 5 (42%) 17 (100%)
Diuretics 2 (22%) 5 (42%) 10 (57%)
LV mass index, g/m2 52 18 117 40* 120 25*
EDVI, ml 77 14 83 25 145 58†‡
LV ejection fraction, % 72 11 67 18 24 11†§
LV developed pressure, mm Hg 117 26 178 46 90 25§
LV EDP, mm Hg 13 3 17 6* 21 7†
Diastolic wall stress, kdyn/cm3 18 9 19 9 38 15†§
Systolic wall stress, kdyn/cm3 70 25 69 32 134 27§
alues are mean  SD. Data were analyzed by analysis of variance followed by post-hoc analysis.
p 0.01 versus control; †p 0.001 versus control; ‡p 0.001 versus AS; §p 0.01 versus AS;
p  0.05 versus control.
Abbreviations as in Table 1.nd arterial endothelial cells secrete ST2 protein. The ST2
rotein synthesis and release was rapid, peaked within 6 h,
nd was blocked by brefeldin, which blocks intracellular
rotein transport (25), confirming that ST2 exits endothe-
ial cells through a secretion pathway responsive to inflam-
atory signals. This finding, together with the relationship
etween serum ST2 and indexes of diastolic load, suggests
hat the vascular endothelium, sensing hemodynamic and
nflammatory status, is a potential source of elevated serum
T2 levels in hemodynamic overload and heart failure.
In this regard, it is noteworthy that ST2 levels failed to
rovide prognostic information in patients with acute
oronary syndrome (26). Interestingly, those authors
oticed the highest serum ST2 levels in chronic alcohol-
cs, patients with systemic sepsis, and concomitant lung
iseases, consistent with studies reporting elevated serum
T2 in pulmonary diseases (13,27). Serum ST2 is also
levated in patients with dengue virus infection (28),
epsis and trauma (29), and in cerebrospinal fluid following
ubarachnoid hemorrhage (30). The broad specificity of ST2
nduction corroborates its nonmyocardial production and may
xplain why ST2 performs well as an independent biomarker
n multimarker studies, providing information that is distinct
rom BNP in cardiovascular disease.
In addition to a cardiovascular biomarker, ST2/ST2L
ignaling is likely to be important in cardiovascular
isease modulation. At the cellular level, soluble ST2
inds to macrophages and down-regulates proinflamma-
ory cytokines, IL-1, IL-6, and tumor necrosis factor-
lpha (14,15). Soluble ST2 can bind to IL-33, the ST2L
igand, to diminish mitogen-activated protein kinase and
uclear factor kappa B signaling (13). Membrane-
nchored ST2L also inhibits IL-1 receptor and innate
thelial Cells
(left). IL-1-beta induced secretion but H2O2 blocked secretion in arterial endo-
ignificantly elevated levels at 3 h and reaches peak values at 6 h (right). Brefel-Endo
al cells
with s
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ence, both ST2L and soluble ST2 negatively regulate
L-1 receptor and Toll-like receptor 4 signaling (12,32).
e present the novel findings that ST2L and IL-33
RNA are expressed in normal and diseased human
Figure 6 IL-33 and ST2 mRNA Levels in Myocardial Biopsies
(A) The IL-33 mRNA levels were decreased in AS hearts compared with the levels
pared with the levels in control hearts. The ST2L levels were similar in CCM heart
human coronary artery endothelium (brown staining). ANOVA  analysis of varianc
Figure 7 Correlation Between ST2L and IL-33 in Leukocytes
Relationship between ST2L and IL-33 mRNA levels in leukocytes from
control, AS, and CCM patients. Abbreviations as in Figures 1, 4, and 5.pyocardium and both are modestly but significantly
ecreased in patients with AS. The mechanism is un-
nown, although it is recognized that soluble versus
embrane-anchored ST2L are regulated separately (7,8).
n addition, we found that IL-33 protein is expressed in
ndothelial cells within coronary arteries suggesting that
L-33 may have a similar function in vascular endothe-
ium that may be regulated by soluble ST2. We report a
emarkable pronounced correlation between ST2L and
L-33 levels in peripheral blood leukocytes, suggesting
hat they are highly coregulated in these cells. Further
tudies are needed to determine the biological relevance
f these observations.
tudy limitations. The present study is limited to patients
ith chronic AS or heart failure. It would be interesting to
nterrogate myocardial production of ST2 protein in acute
yocardial infarction following which serum ST2 levels are
lso increased. Although the lack of transmyocardial ST2
radient argues against cardiac production of serum ST2,
T2 protein production in human adult cardiac myocytes
as not directly tested.
onclusions
his study describes elevated serum ST2 in patients with
hearts. The ST2L mRNA levels were significantly decreased in AS hearts com-
ared with the levels in control hearts. (B) The IL-33 protein was expressed in
 control; other abbreviations as in Figures 1, 4, and 5.in CCM
s comp
e; CONressure overload hypertrophy and congestive or diastolic
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Nonmyocardial ST2 Production and Diastolic Load December 16/23, 2008:2166–74eart failure. Our data support diastolic load as a predom-
nant hemodynamic factor that contributes to ST2 produc-
ion in heart disease. Note that our data indicate that
verloaded myocardium is not a major source of increased
erum ST2. We showed that endothelial cells possess a
unctional ST2 secretory system in vitro, providing proof-
f-concept for ST2 production by the vascular endothelium
n vivo, which can be investigated in future studies.
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